Wisdom Pharma announced that the cumulative deviation value of the closing price increase of the company's stock exceeded 30% for two consecutive trading days, which was an abnormal fluctuation. After verification, there were no corrections or additions to the information disclosed earlier by the company. Recently, operations were normal, no important matters should be disclosed, and the controlling shareholders and actual controllers did not trade the company's shares during the change period. In addition, issuing shares to specific targets is yet to be approved by the Securities Regulatory Commission. The 2026 semi-annual report was disclosed on August 29, reminding investors to be aware of the risks.

Wisdom Pharma announced that the cumulative deviation value of the closing price increase of the company's stock exceeded 30% for two consecutive trading days, which was an abnormal fluctuation. After verification, there were no corrections or additions to the information disclosed earlier by the company. Recently, operations were normal, no important matters should be disclosed, and the controlling shareholders and actual controllers did not trade the company's shares during the change period. In addition, issuing shares to specific targets is yet to be approved by the Securities Regulatory Commission. The 2026 semi-annual report was disclosed on August 29, reminding investors to be aware of the risks.